Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.3.1 (alkaline phosphatase)
 47,916 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

16 patients suffering from Paget's disease were studied before, during and after 3 or 6 month treatment with disodium ethydronate (EHDP) per os. An appreciable improvement in pain symptomatology was noted and at times an evident improvement in audiometry; from the metabolic viewpoint there was a fall in serum alkaline phosphatase and urinary excretion of calcium and hydroxyproline. A study of radiocalcium kinetics demonstrated a reduction in the exchangeable calcium pool and the fractional turnover rate. Histological examination following needle biopsy of the iliac crest showed evident diminution in the active bone cell population (osteoclasts, osteoblasts) and, in certain cases, appearance of osteoid borders.
 ...
PMID:[Treatment of Paget's disease with diphosphonate (disodium ethydronate)]. 81 5

A new radioimmunoassay for human procollagen showed that the sera of 46 of 50 untreated patients with Paget's disease of bone contained increased concentrations of procollagen protein as compared to normal adults. After therapy with disodium etidronate, all the elevated serum procollagen concentrations decreased significantly, falling to normal levels in 33 of 40 patients. The procollagen levels before and after treatment were coordinate with the values for urinary total hydroxyproline and serum alkaline phosphatase activity. The data show that the radioimmunoassay for procollagen is a dependable and useful adjunct to the study of Paget's disease of bone.
 ...
PMID:Radioimmunoassay of procollagen in serum of patients with Paget's disease of bone. 81 38

Scintigraphic and roentgenological studies in 9 patients, treated for Paget's disease, were evaluated before and during treatment and related to the values of serum alkaline phosphatase. On the initial studies--before treatment--25 lesions were found on both scintigram and roentgenogram. One lesion--proven by biopsy--was only seen on the scintigram. The roentgenograms showed no changes during this period, ranging from 6-16 months, except for one lesion with dubious progression. The scintigrams, carried out using 99Tcm-EHDP, showed both a qualitative and quantitative improvement in 7 cases. The ratios of radionuclide accumulation in Pagetoid bone and normal bone corresponded well with the values of serum alkaline phosphatase. In 4 out of 9 cases, however, the scintigram still demonstrated pathologic uptake of radioactivity, while serum alkaline phosphatase levels had dropped to normal values. It is concluded that bone scintigraphy may be of value for the follow up of patients under treatment for Paget's disease.
 ...
PMID:Evaluation of scintigraphic and roentgenologic studies in Paget's disease under treatment. 82 Oct 96

The activity of proline imino-peptidase (EC 3.4.1.4) may provide a measure of collagen degradation, and a method for its estimation in human serum is described. The mean value of this enzyme activity in 48 normal adults of 4.7 mU/l (S.D. 0.9) did not change with sex, age or dietary collagen. In 8 patients with liver disease associated with elevated levels of plasma alkaline phosphatase activity the mean value was normal (4.5 mU/l, S.D. 1.5). However, in 25 patients with untreated Paget's disease of bone, values were significantly increased (mean 7.4 mU/l; S.D. 2.8; p less than 0.001) and were positively correlated with plasma alkaline phosphatase activity (r = 0.75; p less than 0.001) and with urine total hydroxyproline excretion (r = 0.68; p less than 0.001). In patients given disodium ethane-1-hydroxy-1,1-diphosphonate for 3--6 months, serum proline imino-peptidase activity decreased to normal values.
 ...
PMID:Serum proline imino-peptidase activity in normal adult subjects and in patients with Paget's disease of bone. 82 68

10 patients with active symptomatic Paget's disease of bone have been treated for 6 months with disodium etidronate (EHDP) at a dose of 20 mg/kg/day. A statistically significant fall in the serum levels of alkaline phosphatase and urinary hydroxyproline was observed. However, only 2 patients experienced a significant reduction of bone pain. 6 patients were partially improved and 2 patients showed no change. Iliac crest biopsies after treatment demonstrated dimunution of the abnormal structure of the pagetic bone, but also a considerable increase in unmineralized osteoid borders. The future potentialities for treatment of Paget's disease are discussed.
 ...
PMID:[Treatment of 10 cases of symptomatic Paget's disease with etidronate (EHDP)]. 82 10

1. Plasma levels of immunoreactive calcitonin were measured in 22 patients with untreated Paget's disease of bone and in 22 control subjects matched for age and sex. 2. No significant differences in plasma calcitonin were found between patients and control subjects, and hormone levels did not correlate significantly with activity of plasma alkaline phosphatase. 3. These results suggest that Paget's disease of bone is not due to deficient of endogenous calcitonin.
 ...
PMID:Plasma calcitonin in Paget's disease of bone. 84 63

The production of acute hypocalcemia was investigated using either 80 U. MRC of salmon calcitonin or 160 1. mrc of pork calcitonin in 117 subjects (58 patients with Paget's disease, 22 with osteoporosis, 22 with Sudeck-Leriche algodystrophy and 15 control subjects). The results obtained with the two types of calcitonin did not differ. Induced acute hypocalcemia was more pronounced in patients with Paget's disease than in the other subjects studied. In patients with Paget's disease there were statistically significant correlations between the hypocalcemia produced and the initial levels of alkaline phosphatase and total 24 hours urinary hydroxyproline.
 ...
PMID:[A test for acute hypocalcemia using swine and salmon calcitonin]. 84 64

Thirteen patients with symptoms of active Paget's disease of bone, confirmed biochemically and radiologically, were studied. Each patient received a 6 months' course of therapy with human synthetic calcitonin (HCT), starting with 1 mg daily subcutaneously or intramuscularly for the first month and thereafter 3 times per week for 5 months. Twelve patients completed the course of therapy. Ten of the 12 patients derived moderate to great symptomatic improvement from their treatment. The improvement usually became evident 6 weeks after the start of treatment and this improvement persisted in 4 patients from 6 months to 1 year after treatment was stopped. The plasma alkaline phosphatase had fallen from the initial values by a mean of 26% after 6 weeks and 31% after 6 months of treatment. The urinary hydroxyproline likewise had fallen by 42% at 6 weeks and 46% at 6 months. Side-effects were generally mild and self-limiting, with flushing being the most common. It is concluded that human calcitonin is beneficial in the treatment of Paget's disease of bone and may prevent the problems of antibody resistance and allergic phenomena encountered with other preparations of calcitonin.
 ...
PMID:Paget's disease of bone (osteitis deformans) treated with human synthetic calcitonin. 85 Aug 45

Metabolic balance and calcium kinetic studies were performed in four patients with Paget's disease before treatment with salmon calcitonin and during the early and late stages of the treatment, which lasted 9 to 19 months, A significant decrease in bone turnover and 24-hour urine hydroxyproline and serum alkaline phosphatase values was observed in all patients. In contrast, the calcium, phosphorus and magnesium balances did not change significantly. In agreement with this, the partial body calcium, measured by in vivo neutron activation analysis, did not change. Intestinal calcium absorption increased initially, but returned to baseline levels 9 to 19 months after the study began. During the initial period there was a small, significant, but transient decrease in tubular reabsorption of phosphorus; this was accompanied by a significant decrease in serum phosphorus values--probably a direct effect of calcitonin rather than evidence of secondary hyperparathyroidism. Administration of salmon calcitonin to patients with Paget's disease decreases bone turnover without affecting calcium and phosphorus balances.
 ...
PMID:Metabolic balance studies in patients with Paget's disease receiving salmon calcitonin over long periods. 85 28

Coinciding investigations of the 85Sr test and of bone derived serum alkaline phosphatases activity were undertaken in 38 patinets with locomotor system diseases. In 15 patients there was congruence between the positive result of the 85Sr test and an increased activity of B-ALP. In 5 patients there was congruence between negative outcome of B-ALP and negative 85Sr test. The activities of T-ALP, B-ALP, L-ALP and I-ALP were compared with a group of 124 healthy controls. The causes of 18 incongruent results were analysed. In rhizomelic form of ASp, active Paget's disease, osteomalacia and in some forms of osteoporosis there was congruence between increased activity of B-ALP and the positive 85Sr test over the clinically involved area of the locomotor system. In ankylosing spondylitis (without rhizomelic involvement) there may be a moderate fall of B-ALP activity but the 85Sr test is usually positive; this may correspond with metabolic activity in the paravertebral region of the ligaments. Low B-ALP activity and positive 85Sr test in MP may refer to a latent process in the bone apparatus without marked activity of osteoblasts. The fall of B-ALP may be a result of therapy or due to the reduced capacity of B-ALP to be released from the bone. In osteomalacia the rapid fall of 85Sr activity during the test is the cause by the presence of pathological osteoid which may be, even in patients with hypertension, of renal origin. A method was described permitting the evaluation of the process of active incorporation of bone minerals (after 8 days). The activity of the 85Sr test over clinically silent areas (e.g. spine) may indicate a decompensated process in the spine due to an involvement to the large joints. The two methods used in this study are metabolically different (85Sr binds to proteoglycans and inorganic structures of bone tissue, alkaline phosphatase to the activity of osteoblasts) and prove to be clinically valuable. Detailed analysis of the results makes it possible to define the stages of clinical activity of disease and to check more exactly the efficiency of the therapeutic method.
 ...
PMID:[Clinical evaluation of the results of the Sr85 test and of bone alkaline phosphatase isoenzyme activity]. 87 Oct 69


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>